Medical Health & Life Science Research News

Research delivers insight into the Alzheimer’s disease drugs market forecast to 2021

Research delivers insight into the Alzheimer’s disease drugs market forecast to 2021

Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages.

- Advertising -

With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer’s treatment is a high risk, high reward market.

- Advertising -

Drugs currently available in the market have reached maturity; patent of leading drugs have expired. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies.

Browse the report: www.orbisresearch.com/reports/inde…-analysis-to-2021

Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Analysis
In 2016, the global market for Alzheimer’s disease drugs was dominated by Namenda, Memary, Aricept and Exelon. The combined market share of these four drugs was over 80% in the year 2016.
Ebixa, Razadyne/Reminyl, Rivastach and Nootropil are the other popular drugs in the Alzheimer’s disease market.
With the patent expiration of popular drugs the sales of the Alzheimer’s drugs have also declined. However, there are several pipeline drugs like Gantenerumab, Crenezumab and Aducanumab among others which are likely to hit the market during the period 2019 – 2020.

Global Alzheimer’s Disease Country Wise Analysis
In the Alzheimer’s disease drugs market, the United States is the largest market.
Japan is the second leading market for Alzheimer’s disease drugs market accounting for XXX% market share in 2016.
China stands at the third spot in the global Alzheimer’s disease drugs market being followed by India with XXX% share in the same year.
The EU5 countries together accounted for over 10% share of the global Alzheimer’s disease drugs market in 2016.

Request a sample of the report: www.orbisresearch.com/contacts/request-sample/340259

iGATE RESEARCH report titled “Global Alzheimer’s Disease Drugs Market, Regional Analysis & Forecast, Major Deals & Funding, and Pipeline Drugs Analysis to 2021” is a 189 Page report with 74 Figures and 14 Tables. This report provides a comprehensive assessment of the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer’s Disease – Country Wise Drugs Market, Country Wise Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape, Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s Disease Drugs Market.

The Alzheimer’s Disease Drugs Market has been analyzed from 8 View Points:
1. Alzheimer’s Disease – Drugs Sales and Forecast
2. Alzheimer’s Disease – Pipeline Drugs Sales Forecast
3. Alzheimer’s Disease Drugs – Country Wise Market and Forecast
4. Alzheimer’s Disease – Country Wise Prevalence and Forecast
5. Alzheimer’s Disease – List of Pipeline Drugs in Various Phase of Development
6. Alzheimer’s Disease – Major Deals in Alzheimer’s Drugs Market
7. Alzheimer’s Disease – Funding in Alzheimer’s Disease Research
8. Alzheimer’s Disease Drugs Market – Driving Factors & Challenges

The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:
1. Exelon
2. Razadyne/Reminyl
3. Memary
4. Ebixa
5. Aricept
6. Rivastach
7. Namenda
8. Nootropil
9. Namzaric

The 3 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:
1. Gantenerumab
2. Crenezumab
3. Aducanumab

The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:
1. United States
2. France
3. Germany
4. Italy
5. Spain
6. United Kingdom
7. Japan
8. China
9. India

List of Pipeline Alzheimer’s Disease Drugs in Various Phase of Development
1. Phase I
2. Phase II
3. Phase III

The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:
1. Strategic Alliance
2. Licensing Agreement
3. Collaboration Deals
4. Mergers and Acquisitions

List of Tables:
Table 3-1: Country Wise - Alzheimer’s Disease Drugs Market Share (Percent), 2013 - 2016
Table 3-2: Country Wise - Forecast for Alzheimer’s Disease Drugs Market Share (Percent), 2017 - 2021
Table 7-1: Alzheimer's Disease Drug Development - Agents Currently in Phase I of Development, (As of May 2017)
Table 7-2: Alzheimer's Disease Drug Development - Agents Currently in Phase II of Development, (As of May 2017)
Table 7-3: Alzheimer's Disease Drug Development - Agents Currently in Phase III of Development, (As of May 2017)
Table 7-4: Alzheimer's Disease - Immunotherapies in Clinical Trials for Alzheimer's Disease, (As of May 2017)
Table 8-1: Global Alzheimer’s Disease Drugs Market - Strategic Alliance, 2003 - 2015
Table 8-2: Global Alzheimer’s Disease Drugs Market - Licensing Agreement, 2007 - 2017
Table 8-3: Global Alzheimer’s Disease Drugs Market - Collaboration Deals, 2005 - 2017
Table 8-4: Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions, 2008 - 2016
Table 9-1: BrightFocus Foundation - Alzheimer’s Disease Research Funding (Million US$), 2010 - 2016
Table 10-1: Global - Ageing Indicators (Percent), 2011/2012 - 2050
Table 10-2: Global - Population (Number), 2011/2012 - 2050
Table 10-3: Ten Countries or Areas with the Aging Populations 1950,1980,2013,2050 & 2100(Medium Variant)

List of Figures:
Figure 2-1: Global - Alzheimer’s Disease Drugs Market (Million US$), 2010 - 2016
Figure 2-2: Global - Forecast for Alzheimer’s Disease Drugs Market (Million US$), 2017 - 2021
Figure 2-3: Global - Alzheimer’s Disease Prevalence (Million), 2010 - 2016
Figure 2-4: Global - Forecast for Alzheimer’s Disease Prevalence (Million), 2017 - 2021
Figure 4-1: Global - Exelon Drugs Sales (Million US$), 2003 - 2016
Figure 4-2: Global - Forecast for Exelon Drugs Sales (Million US$), 2017 - 2021
Figure 4-3: Global - Razadyne/Reminyl Drugs Sales (Million US$), 2010 - 2016
Figure 4-4: Global - Forecast for Razadyne/Reminyl Drugs Sales (Million US$), 2017 - 2021
Figure 4-5: Global - Memary Drugs Sales (Million US$), 2011 - 2016
Figure 4-6: Global - Forecast for Memary Drugs Sales (Million US$), 2017 - 2021
Figure 4-7: Global - Ebixa Drugs Sales (Million US$), 2003 - 2016
Figure 4-8: Global - Forecast for Ebixa Drugs Sales (Million US$), 2017 - 2021
Figure 4-9: Global - Aricept Drugs Sales (Million US$), 2009 - 2016
Figure 4-10: Global - Forecast for Aricept Drugs Sales (Million US$), 2017 - 2021
Figure 4-11: Global - Rivastach Drugs Sales (Million US$), 2011 - 2016
Figure 4-12: Global - Forecast for Rivastach Drugs Sales (Million US$), 2017 - 2021
Figure 4-13: Global - Namenda Drugs Sales (Million US$), 2003 - 2016
Figure 4-14: Global - Forecast for Namenda Drugs Sales (Million US$), 2017 - 2021
Figure 4-15: Global - Nootropil Drugs Sales (Million US$), 2004 - 2016
Figure 4-16: Global - Forecast for Nootropil Drugs Sales (Million US$), 2017 - 2021
Figure 4-17: Global - Namzaric Drugs Sales (Million US$), 2015 - 2016
Figure 4-18: Global - Forecast for Namzaric Drugs Sales (Million US$), 2017 - 2021

News From

Orbis Research - Rendering Conscientious ResearchOrbis Research
Category: Market Research Publishers and RetailersCompany profile: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...